Combating Meningococcal Disease in Vulnerable Populations
Pfizer's vaccines, Nimenrix® (meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine) and Trumenba® (Meningococcal Group B Vaccine), help provide countries and health care providers with the ability to broadly protect against this uncommon disease that is unpredictable and potentially deadly. We continue to build Nimenrix manufacturing capabilities with investment in our manufacturing sites. In many parts of the world, Nimenrix is indicated from two months of age.
We also made significant progress in expanding the reach of Trumenba, with launches across the globe. This broader availability reinforces Pfizer's dedication to advancing important vaccines that can help protect adolescents and adults.
Ian Read: Contributions to Improving Human Health
Albert Bourla: Breakthroughs that Change Patients' Lives
Ushering in a New Era of Pfizer R&D Productivity
Advancing Our Leading JAK Science
Overcoming Therapy-Resistant Disease
Tackling Respiratory Syncytial Virus (RSV) Through Breakthrough Science and Technology
Catalyzing Innovations in Global Health
Contributing to the UN Sustainable Development Goals
Supporting Digital Health Start-Ups
Improving the Health of Women and Their Families